TCGA-CR-6481-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.560
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- COMPLEMENT+0.380
- INFLAMMATORY_RESPONSE+0.360
- IL2_STAT5_SIGNALING+0.330
- E2F_TARGETS+0.310
- G2M_CHECKPOINT+0.260
- KRAS_SIGNALING_UP+0.260
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- MYOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- DNA_REPAIR-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.150
- MYC_TARGETS_V1-0.140
- TNFA_SIGNALING_VIA_NFKB-0.140
- PANCREAS_BETA_CELLS-0.110
- TGF_BETA_SIGNALING-0.110
- P53_PATHWAY-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TX-01A-11R-A084-07 | — | C | 0.819 |
| 2 | SAMN03290947 | — | — | 0.787 |
| 3 | b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc | — | — | 0.771 |
| 4 | TCGA-D8-A1JG-01B-11R-A13Q-07 | — | C | 0.771 |
| 5 | MNG623 | — | — | 0.757 |
| 6 | TCGA-BH-A0BW-01A-11R-A115-07 | — | D | 0.755 |
| 7 | TCGA-E2-A159-01A-11R-A115-07 | — | C | 0.743 |
| 8 | 20020049.LumB | — | D | 0.739 |
| 9 | 20110002.Her2HRneg | — | D | 0.738 |
| 10 | TCGA-E9-A243-01A-21R-A169-07 | — | D | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |